Pickering
Anthony Pickering, Hoofddorp NL
Patent application number | Description | Published |
---|---|---|
20150149785 | GENERATING FINGERPRINTED CONTENT DATA FOR PROVISION TO RECEIVERS - A method for generating, from initial content data, output content data for provision to one or more receivers, wherein the initial content data is encoded according to a coding scheme, wherein for a quantity of data encoded according to the coding scheme, the coding scheme provides a mechanism for including in the quantity of encoded data additional data such that a decoder for the coding scheme, upon decoding the quantity of encoded data, does not use the additional data to generate decoded data, the method comprising: selecting one or more portions of the initial content data; for each selected portion, generating a data construct that comprises a plurality of data structures, each data structure comprising data, including a version of the selected portion, that is encrypted using a corresponding encryption process different from each encryption process used to encrypt data in the other data structures, wherein the data construct is arranged such that using a decryption process that corresponds to the encryption process for one data structure on the encrypted data in each data structure in the data construct produces a quantity of data encoded according to the coding scheme that uses the mechanism so that a decoder for the coding scheme would not use any data structure in the data construct other than said one data structure; and using the generated data constructs in the initial content data instead of their corresponding selected portions to form the output content data. | 05-28-2015 |
Gary Pickering, Port Colborne CA
Patent application number | Description | Published |
---|---|---|
20120107467 | METHOD FOR REDUCING METHOXYPYRAZINES IN GRAPES AND GRAPE PRODUCTS - The present application described a method of reducing methoxypyrazines (MPs) in grapes or grape products comprising: (a) contacting the grape or grape product with a protein that binds to MPs at a pH of about 3 to about 4 to form a protein-MP complex; and (b) removing the protein-MP complex from the grape or grape product. Also described is a method of removing MPs from samples comprising contacting the sample with a polyethersulfone membrane. | 05-03-2012 |
Geoff Pickering, Calgary CA
Patent application number | Description | Published |
---|---|---|
20120123877 | POINT OF INTEREST TRACKING WITH SPECIFIC RETAILER ACCREDITATION - A method and system is provided for crediting presenters of product advertisements for purchases related to a consumer's initial point of interest. A presenter provides a previously generated, point of interest tracking (POIT) code on advertising media, the POIT code having an internet address for fulfillment website site, and the indentify of the presenter embedded therein. A consumer scans the POIT Code on an e-device and establishes communication with the fulfillment website, the presenter identity being extracted and tracked, any purchases thereafter being credited to the presenter. Vendors can now identify and remunerate an initial retailer or presenter for their role in closing the cycle from a consumer's point-of-interest through purchase. | 05-17-2012 |
Geoffrey J. Pickering, London CA
Patent application number | Description | Published |
---|---|---|
20140179601 | FGF-9 AND ITS USE RELATING TO BLOOD VESSELS - There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising a first isolated nucleic acid molecule that encodes a FGF-9 polypeptide and optionally one or more isolated nucleic acid molecule that encodes another angiogenic polypeptide. There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising administering an effective amount of a composition comprising an isolated FGF-9 polypeptide and one or more other angiogenic polypeptides. The compositions provided herein may be useful for controlling angiogenesis and/or vasculogenesis. | 06-26-2014 |
Gisele Pickering, Clermont-Ferrand FR
Patent application number | Description | Published |
---|---|---|
20140378551 | Composition for the Prophylactic Treatment of Neuropathic Pain - The invention relates to an analgesic composition containing memantine. According to the invention, such a composition is administered daily to a human patient having to undergo a surgical operation, over a period ranging from one day to a plurality of days before said surgical operation, in order to prevent and treat the development of post-operative neuropathic pain in this same patient. | 12-25-2014 |
Graham Pickering, Victoria AU
Patent application number | Description | Published |
---|---|---|
20110233295 | WATER DISCHARGE DEVICE - There is disclosed a water discharge device that has a water flow path that extends from an inlet through an outlet chamber to an outlet spout; a valve assembly for opening and closing the water flow path; a heating element for heating the outlet chamber and spout to evaporate moisture on internal surfaces of the outlet chamber and spout when the flow path is closed by the valve assembly, the heating element being remote from the flow path; and a controller for controlling operation of the valve assembly and the heating element, the controller including a switch that is operated directly or indirectly by a user to control the opening of the water flow path. | 09-29-2011 |
J. Geoffrey Pickering, London CA
Patent application number | Description | Published |
---|---|---|
20110104132 | FGF-9 AND ITS USE RELATING TO BLOOD VESSELS - There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising a first isolated nucleic acid molecule that encodes a FGF-9 polypeptide and optionally one or more isolated nucleic acid molecule that encodes another angiogenic polypeptide. There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising an isolated. The compositions provided herein may be useful for controlling angiogenesis and/or vasculogenesis. | 05-05-2011 |
John Geoffrey Pickering, London CA
Patent application number | Description | Published |
---|---|---|
20080318892 | METHODS AND FORMULATIONS FOR PROTECTING CELLS, AND FOR TREATING DISEASES AND CONDITIONS BY OPTIMIZING THE INTRACELLULAR CONCENTRATION OF NAD - Pharmaceutical and cosmetic formulations and methods for optimizing the intracellular concentrations of NAD are provided. The present methods and compounds relate to the use of PBEF, PRPP and various forms of nicotinamide, individually or in combination, for therapeutic, cyto-protective, cosmetic and anti-aging purposes. PBEF, PRPP and nicotinamide, individually or in combination, as administered according to the invention, increase the metabolic fitness, health and performance of the cell, and thereby increase the cell's level of health during its lifecycle. By way of the present formulations and methods, optimizing the intracellular concentration of NAD+ facilitates a balance among the numerous intracellular interactions of NAD+, and its related pathways, such that the health of the cell and its resistance to stress and trauma are increased. This increased robustness attendant to the invention also facilitates the delay of apoptosis. | 12-25-2008 |
20090035275 | Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of NAD - Pharmaceutical and cosmetic formulations and methods for optimizing the intracellular concentrations of NAD are provided. The present methods and compounds relate to the use of PBEF, PRPP and various forms of nicotinamide, individually or in combination, for therapeutic, cyto-protective, cosmetic and anti-aging purposes. PBEF, PRPP and nicotinamide, individually or in combination, as administered according to the invention, increase the metabolic fitness, health and performance of the cell, and thereby increase the cell's level of health during its lifecycle. By way of the present formulations and methods, optimizing the intracellular concentration of NAD | 02-05-2009 |
Kim Pickering, Hamilton NZ
Patent application number | Description | Published |
---|---|---|
20140031490 | GLYCEROL BASED UNSATURATED POLYESTER RESINS AND RAW MATERIALS THEREFOR - The invention relates to a mixture of glycerol, mono-, di- and triacetylglycerolester in which the amount of tri-ester is less than 15 mol %, the amount of glycerol is less than 25 mol %, the amount of monoester is about 20 mol % or more, more preferred about 30 mol % or more and the amount of diester is about 20 mol % or more preferred about 40 mol % or more. The invention further relates to methods to prepare such glycerolacetylester mixtures, and to the use thereof in the preparation of unsaturated polyesters. Polyesters comprising said glycerolacetylester mixtures are made from a higher amount of raw materials than obtainable from renewable resources. | 01-30-2014 |
Kim Louise Pickering, Hamilton NZ
Patent application number | Description | Published |
---|---|---|
20100234515 | PLASTICS MATERIAL - The present invention relates to a method of manufacturing a plastic material from a protein source, the method characterised by the following steps; i) treating the protein source with at least one denaturing agent to break interactions between proteins or portions thereof, and ii) treating the denatured protein source with sufficient pressure and temperature to consolidate the denatured protein source into a plastic material. | 09-16-2010 |
Mark Pickering, Dublin IE
Patent application number | Description | Published |
---|---|---|
20120269762 | CAUSAL THERAPY OF DISEASES OR CONDITIONS ASSOCIATED WITH CNS OR PNS DEMYELINATION - The invention broadly relates to the use of the Active in the causal treatment of a disease caused by axonal demyelination, in which the Active maintains the integrity of myelination (for example by promoting remyelination, and/or preventing demyelination, of the axonal sheaths). The invention is particularly directed to the causal treatment of CNS demyelination diseases, for example MS, especially primary progressive MS and/or relapse remitting MS, and PNS demyelination diseases, for example Charcot-Marie-Tooth Disease. The Active of the invention may be suitably administered when a patient is in relapse (i.e. upon relapse), and be continued while the patient is in relapse, with a view to attenuating the severity of the relapse, and/or accelerating disease remission. Alternatively, the Active may be administered continuously with a view to prolonging the remission period, and/or attenuating the severity of the relapse, and/or preventing relapse. The invention also relates to the use of the Active as a treatment for symptoms of demyelination disease, especially MS, selected from vision deficits, motor control deficits, and sensation deficits. | 10-25-2012 |